Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Omega-3 fatty acids, particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), have been studied for their potential role in managing irritability, especially in neuropsychiatric conditions such as attention-deficit/hyperactivity disorder (ADHD), depression, and autism spectrum disorder (ASD). The scientific rationale is based on omega-3’s anti-inflammatory properties and their critical function in brain cell membrane fluidity and neurotransmission. Several randomized controlled trials and meta-analyses suggest that omega-3 supplementation may reduce irritability and aggression in certain populations.

For example, studies in children with autism or ADHD have shown modest reductions in irritability and behavioral problems with omega-3 supplementation. A 2016 meta-analysis published in Neuropsychopharmacology found that omega-3 supplementation had a small but significant effect in reducing aggression and irritability in children and adolescents with disruptive behavior disorders. Similarly, some research in adults with mood disorders indicates potential benefits, although results are mixed and the effect size is generally modest.

While the evidence is not overwhelming or universally consistent, it is stronger than anecdotal or traditional claims. Most clinical guidelines consider omega-3 as an adjunctive treatment, not a primary therapy, for irritability—particularly when it is associated with neurodevelopmental or psychiatric conditions. Further research is needed to clarify optimal dosing and the populations most likely to benefit.

More about omega-3 fatty acids
More about Irritability

Other ingredients used for Irritability

Other health conditions supported by omega-3 fatty acids

Products containing omega-3 fatty acids

Nature's Sunshine Flax Seed Oil (With Lignans)